Objectives: To investigate the molecular characteristics and epidemiology of metallo-blactamase-producing Pseudomonas aeruginosa from urine of urinary tract infection patients in Hyogo Prefecture, Japan. Methods: Carbapenem-resistant P. aeruginosa isolated from the urine of 21 urinary tract infection patients in three general hospitals in Hyogo Prefecture (Japan) were collected between 2007 and 2014. Their antibiotic susceptibilities, metallo-b-lactamase screening test, metallo-b-lactamase gene sequencing, multilocus sequence typing and repetitive-sequence-based polymerase chain reaction were determined for epidemiological analyses to investigate the genetic characteristics. Results: Out of 21 isolates, 13 (61.9%) were positive for metallo-b-lactamase. There were 11 (52.4%) isolates with IMP-1 in them, one (4.5%) isolate with IMP-7 and one (4.5%) isolate with VIM-1. Metallo-b-lactamase-positive isolates were mainly identified as ST235, and metallo-b-lactamase-negative isolates were STs 357, 277, 234, 439 and 639. Repetitivesequence-based polymerase chain reaction showed metallo-b-lactamase-positive isolates were grouped in eight clusters, and ST235 isolates with IMP-1 from three hospitals belonging to the identical group I, the other ST235 isolates with IMP-7 and VIM-1 were from two hospitals belonging to group II. Conclusions: Metallo-b-lactamase-positive P. aeruginosa of ST235 isolates with IPM-1 were mainly identified from the urine of urinary tract infection patients in Hyogo, Japan. A ST235 isolate with VIM-1 was found for the first time. Further investigation is necessary to follow the spread of metallo-b-lactamase-positive isolates.
Introduction
Pseudomonas aeruginosa is one of the major opportunistic and nosocomial pathogens that often causes severe UTI and fatal infections especially in immunocompromised patients. 1 Carbapenems, such as IPM and MEPM, have often been used for P. aeruginosa-causing infections, but we often encounter the emergence of carbapenem-resistant P. aeruginosa.
Several molecular epidemiological techniques are required in order to monitor whether MBL-producing P. aeruginosa is clonally spread or not. 4 As a molecular epidemiological technique: MLST, based on nucleotide sequencing of seven housekeeping genes in the bacterial chromosome, provides information as the STs on bacterial phylogeny, and has been increasingly applied to compare with worldwide strains by observation of the same STs. 7 Then, MLST analysis revealed that P. aeruginosa clones, such as ST235, ST244, ST175 and ST357, have spread worldwide. 5 Furthermore, the rep-PCR, based on the differences of repetitive extragenic palindromic DNA sequence alignments in the bacterial chromosome, is mainly used to characterize the genetic diversity for confirming an outbreak in a hospital or region by grouping strains belonging to the same ST isolates. 8 However, few studies have reported the epidemiological methods using MLST or rep-PCR for genotyping among MBL-producing P. aeruginosa isolates in Asian countries. 9 The current situation regarding clonal diffusion that has the potential to spread as highly antibiotic-resistant strains needs to be investigated.
In the present study, to reveal the current spread and cluster analysis of UTI-causative carbapenem-resistant P. aeruginosa, we investigated the molecular characteristics and epidemiology of carbapenem-resistant P. aeruginosa isolates collected in Hyogo, Japan. This study offers urologists treating patients with UTI or other infections information regarding highly-resistant bacteria.
Methods

Bacterial isolates
We collected 21 carbapenem-resistant P. aeruginosa clinical isolates consecutively from the urine of UTI patients at three general hospitals in Hyogo Prefecture between 2007 and 2014. Each isolate was obtained from an individual patient. Hyogo Prefecture is located in midwest Japan. These bacteria were from three hospitals in the Hyogo area, and A hospital (934 beds), B hospital (357 beds) and C hospital (330 beds). The proportion of P. aeruginosa-causing UTI was as follows: 6.2% at A hospital, 13.8% at B hospital and 4.7% at C hospital in 2017. The carbapenem resistance rates of P. aeruginosa were as follows: 8.4% at A hospital, 6.0% at B hospital and 2.4% at C hospital in 2017. Carbapenem resistance was diagnosed as IPM or MEPM resistance according to the CLSI standard, which showed minimum inhibitory concentrations values at >4 lg/mL of IPM or MEPM. 10 
Patient backgrounds
We examined the backgrounds of the patients who had UTI-causing P. aeruginosa UTI, such as age, sex, urinary tract catheter use, immunocompromised, antibiotic use and underlying diseases.
Ethical approval
The present study was approved by the institutional review board of Kobe University (Nos. 1494 and 1872). This research was carried out in compliance with the relevant laws and guidelines, in accordance with the ethical standards of the 1964 Helsinki Declaration. All human participants were directly involved in the study for the collection of isolates, and informed consent was obtained from all individual participants included in the study.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was carried out using the disc diffusion method, which was estimated using the procedure described in the CLSI document M02-A11. We used the following eight antibiotics: PIPC/TAZ, AZT, CAZ, CFPM, CPFX, LVFX, AMK and CL (Becton, Dickinson and Company, Sparks, MD, USA) according to the CLSI guideline. 10 P. aeruginosa ATCC27853 was used as a quality control. Carbapenemase producers were phenotypically identified by the Modified Hodge test, 10 and MBL-producers were detected by the double-disk synergy test using CAZ, IPM, MEPM, AZT (Becton, Dickinson and Company) and sodium mercapto-acetate disks (3 mg; Eiken Chemical, Tokyo, Japan) following the manufacturer's instructions. 11 
PCR amplification and nucleotide sequencing
Genomic DNA was prepared by the UltraClean Microbial DNA Isolation Kit (MO BIO Labs, Solana Beach, CA, USA) according to the manufacturer's recommendations. All isolates were assessed for MBL types by PCR and DNA sequencing. PCR primers and conditions for the amplification of each carbapenamase gene were used as described in previous reports (NDM-1, IMP-1, IMP-2, VIM-1, VIM-2, KPC and OXA), [12] [13] [14] [15] [16] [17] and the PCR condition was as follows: denaturation at 95°C for 3 min, followed by 35 cycles at 95°C for 30 s, at 55°C for 60 s, and at 72°C for 60 s, and elongation at 72°C for 5 min. The PCR products of these genes were purified by QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany), and sequencing was carried out at Operon Biotechnologies (Tokyo, Japan). Similarity determination of nucleotide sequences was compared with sequence databases using BLAST (http://blast.ncbi.nlm.nih. gov/).
MLST
MLST typing of the P. aeruginosa isolates was carried out by using PCR according to seven housekeeping genes (acsA, aroE, guaA, mutL, nuoD, ppsA and trpE) on the P. aeruginosa MLST website (http://pubmlst.org/paeruginosa/). The nucleotide sequences of these genes were compared with the sequences submitted to the MLST database in order to determine the allelic numbers and STs.
Rep-PCR
For the purpose of investigating the clonal relatedness of P. aeruginosa isolates, rep-PCR was carried out using the DiversiLab system (bioM erieux, Grenoble, France), as described in the standard protocol provided by the manufacturer (DiversiLab Pseudomonas kit; bioM erieux). The rep-PCR patterns are resolved through a gel-based fluidic microarray in an Aglient Bioanalyzer 2100 using DNA LabChip reagents (Aglient Technologies, Palo Alto, CA, USA). The results were analyzed with DiversiLab software (version 3.3.40) using the Kullback-Leibler method to determine distance matrices, and the dendrogram was based on Dice's coefficient of similarity with the unweighted pair group method using an arithmetic averages clustering algorithm.
Isolates showing >95% similarity were considered to be related. 18 
Statistical analysis
Statistical analyses were carried out by Fisher's exact test using PASW Statistics 17.0 software (SPSS, Chicago, IL, USA), with P < 0.05 considered to show statistical significance.
Results
Sample information
The details of the sample are shown in Table 1 . There were 12 men and nine women, and the median age was 74 years (range 26-96 years), of whom 17 (81.0%) used a catheter and four (19.0%) were immunocompromised. Spinal cord injury was the most common underlying disease (23.8%). All of the patients had a complicated UTI. Three patients (A1-A3) were from A hospital, 11 patients (B1-B11) were from B hospital and seven patients (C1-C7) were from C hospital. 
Antimicrobial susceptibilities
Prevalence of carbapenemase-positive isolates
Among carbapenemase-positive isolates, 12 (57.1%) isolates had bla IMP-1 , and one (4.5%) isolate had bla VIM-1 . These carbapenemases were MBL types. Of the bla IMP-1 positive isolates, 11 (52.4%) isolates belonged to the IMP-1 type, and one (4.5%) isolate belonged to the IMP-7 type. Of the bla VIM-1 -positive isolates, all belonged to the VIM-1 type (Table 1 ).
MLST
Our tested 21 isolates belonged to six kinds of STs by MLST: the most prevalent was ST235 (14 isolates, 66.7%), followed by ST357 (2 isolates, 9.5%), ST639 (2 isolates, 9.5%), ST234 (1 isolate, 4.8%), ST277 (1 isolate, 4.8%) and ST439 (1 isolate, 4.8%; Table 1 ).
Rep-PCR
As shown in Figure 1 , all 21 isolates were grouped into eight kinds of rep-PCR clusters (groups a-h). The most common cluster showing >95% similarity was group "a," which accounted for 11 (52.4%) isolates, revealing the trend of the same cluster (a) from the same hospital (B hospital; 8/11, 72.7%), and consisted of ST235 with IMP-1 from three hospitals, but the year of samples taken were separated. Three isolates with IMP-7, VIM-1 or not belonged to group "b" from two hospitals (B hospital and C hospital). Two isolates without MBL belonging to group "c" were ST357 from C hospital. Other isolates were singletons.
Therapies
In hospital B, ST235 strains with IMP-1 had variable susceptibilities for antibiotics, PIPC/TAZ, AZT or AMK. The treatments for the patients having these strains were performed by i.v. or oral CTM, oral LVFX, oral CCL and/or oral CFDN in most cases in B hospital. One of three patients who had isolates of intermediate susceptibility for PIPC/TAZ administered ABPC/SBT. The treatment for the patient who had the AMK-resistant strain was unknown because the patient was transferred to another hospital.
Discussion
Through the epidemiological data of present study, urologists can gain an understanding of what the highly antibiotic-resistant strains of P. aeruginosa are and how they are spread. For instance, as suggested in the literature, which describes the outbreak of such resistant strains as extended spectrum b-lactamase producers with the same cluster in the hospital. Usually this outbreak could be caused by plasmid mediation, which often occurs as a result of insufficient infection control measures for handling the patients' urine, for instance. We urologists need to be aware of this issue and educate medical staff regarding the prevention of this kind of outbreak of antibiotic-resistant strains, such as MBL producers.
MBL-producing bacteria is one of the carbapenemase-producing bacteria, and shows high resistance to various kind of antibiotics, which often causes severe infection and possibly disseminates. 19 Basically, general urologists take care of those patients not only for cancer, but also infection. Mawatari et al. reported that ≥40% of the total infections treated by urological doctors are UTIs. 20 If this is the case, in accordance with epoch change, knowledge of only antibiotics is not enough for urologists, but knowledge of bacteria and why the antibiotic-resistant strains occur and spread is essential. This is because prevention of repeated treatment failure is key after further emergence of antibiotic-resistant bacteria, and informed consent and instructions for patients not to mix with other people, including family and older patients, are necessary.
MBL is a class B carbapenemase and is mostly produced by Enterobacteriaceae or Pseudomonas. 21 The former has been relatively well studied, but not in the latter; therefore, we focused on P. aeruginosa with MBL production. We found these MBL-producing P. aeruginosa isolates were highly resistant to most antibiotics examined, except CL. In the relationship between P. aeruginosa and MBL genes, IMP-1 isolated in Japan were highly resistant to all b-lactams, aminoglycoside and fluoroquinolones;
5 however, the present data showed that AMK had some possibility as a therapeutic strategy for this (susceptibility rate: 18/21, 85.7%). In addition, CL was also added as a therapeutic strategy for carbapenemresistant Gram-negative bacteria infections. 22 Further study with newer strains needs to be carried out to gain an understanding of the current situation.
Our MBL-producing P. aeruginosa isolates were typed into IMP-1, IMP-7 or VIM-1, and those with IMP-1 were first discovered worldwide in the late 1980s and spread to Japan in 1991. 4, 6 To date, the isolates with IMP-1 have mainly spread in Asian regions. 5, 23 P. aeruginosa with VIM-1 or IMP-7 was also first found in 1999 or 2002, respectively, and has been found in Asian regions (isolated in Japan in 2010) and European regions as well. 4, 5, 24, 25 In the present study, the most common MBL type in Japan was IMP-1, whereas there was only one strain of P. aeruginosa carrying VIM-1 or IMP-7. One possible reason was that our strains with IMP-1 were the old type, which were isolated in 2007-2014, and those with VIM-1 and IMP-7 were isolated in 2013-2014. Further study is required to monitor the spread of these strains.
This kind of study requires further epidemiological investigation of the cluster of bacteria by MLST to gain knowledge of how these strains spread and which ST is mainly seen in which region of the world. 26 Our MLST analysis showed that P. aeruginosa isolates with IMP-1, IMP-7 or VIM-1 were identified as ST235. MBL-producing ST235 isolates seem to be the most widely spread clones associated with multidrug resistance and are frequently detected in several countries. 27 P. aeruginosa ST235 and ST357 isolates with IMP-1, IMP-7 or VIM-1 have been identified in several countries, including Central Europe. 4 30 We reported in our previous study that the strains isolated in B hospital have spread. 31 In the present study, to confirm the spread of these strains in the Hyogo area, we added the strains isolated in two hospitals, A hospital as remote region and C hospital as region close to B hospital. As a result, the outbreak strains in B hospital might be spread in the Hyogo area. These strains with varied antimicrobial susceptibilities were spread under the various underlying diseases.
We showed significant results regarding our knowledge of the current spread of MBL-producing P. aeruginosa, but we would like to emphasize the study limitations. First, this was a retrospective study with a small number of strains which were highly resistant to many kinds of antibiotics and with limited clinical information. Second, further epidemiological analyses are required, because few studies reported the association between MBL types and ST clones by MLST and rep-PCR. We showed the trend of the same cluster (a) from the same hospital (B hospital; 8/11, 72.7%) by dendrography, as did our previous study and other studies. [31] [32] [33] Third, mechanistic studies are lacking, for instance, on bacterial porin or efflux pump. Fourth, full clinical data were not available for investigation, including the duration and decision to use combination therapy. Further studies with a greater number of institutions and patients, longer periods, and epidemiological and clinical information should be carried out for definitive conclusions.
In conclusion, MBL-producing P. aeruginosa ST235 isolates with IPM-1 were mainly identified in Hyogo, Japan, and VIM-1 was found for the first time, and had significantly higher resistance rates to most antibiotics. Future investigation will be undertaken for current spread and cluster analysis of MBL-producing bacteria.
